Table 3. Relationship between clinicopathological characteristics and overall survival in GnP patients.
| Number of cases | 1 year survival rate (%) | P value | ||
|---|---|---|---|---|
| Sex | Male | 15 | 90.0 | 0.8847 |
| Female | 25 | 95.2 | ||
| Resectability | UR | 2 | 100 | N.D. |
| BR | 38 | 93.3 | ||
| Age | ≥67 | 21 | 87.5 | N.D. |
| <67 | 19 | 100 | ||
| Reduction rate of CEA level (%) | ≥-6.3 | 19 | 87.5 | 0.4820 |
| <-6.3 | 20 | 100 | ||
| Reduction rate of CA19-9 level (%) | ≥-92 | 19 | 92.3 | 0.2471 |
| <-92 | 20 | 94.4 | ||
| Reduction rate of tumor volume (CT, %) | ≥-46 | 20 | 92.9 | 0.1279 |
| <-46 | 20 | 94.1 | ||
| Adjuvant | + | 36 | 80.1 | 0.0476* |
| - | 4a | 0 | ||
| Histologic differentiation | Well | 11 | 100 | 0.7028 |
| Moderately/poorly | 29 | 90.9 | ||
| Stromal pattern | Scirrhous | 5 | 66.7 | 0.3066 |
| Intermediate/Medurally | 35 | 96.4 | ||
| T | 3 | 38 | 93.1 | N.D. |
| 4 | 2 | 100 | ||
| N | 0 | 15 | 90.0 | 0.6699 |
| 1 | 25 | 95.2 | ||
| Surgical margin | 0 (Negative) | 34 | 92.0 | 0.9576 |
| 1 (Positive) | 6 | 100 | ||
| Histologic evaluation of treatment effect | ||||
| Japan Pancreas Society | 1a | 19 | 88.2 | 0.9268 |
| 1b | 17 | 100 | ||
| 2 | 4 | 100 | ||
| Evans | I | 19 | 88.2 | 0.9268 |
| IIa | 17 | 100 | ||
| IIb | 4 | 100 | ||
| CAP | 2 | 2 | 100 | N.D. |
| 3 | 38 | 93.3 | ||
| Microscopic tumor volume (mm3) | ≥16950 | 18 | 94.1 | 0.1749 |
| <16950 | 22 | 92.9 | ||
| No. of lymph nodes with metastasis | ≥2 | 17 | 93.3 | 0.6699 |
| <2 | 23 | 93.8 | ||
| Tumor-stroma ratio (%) | ≥40 | 22 | 94.1 | 0.5599 |
| <40 | 18 | 92.9 | ||
| Inflammation | Lymphoplasmacytic | 9 | 100 | 0.7517 |
| Neutrophilic | 31 | 91.3 | ||
| Fibrosis in the tumor | Mature | 34 | 92.3 | N.D. |
| Immature | 6 | 100 | ||
| Encapsulating fibrosis | 0 (Negative) | 14 | 81.8 | 0.0302* |
| 1 (Positive) | 26 | 100 | ||
*, P<0.05 by Kaplan-Meier analysis. Patients were divided into two groups according to median value of each parameter. Histologic evaluation of treatment effect according to criteria of the Japanese Pancreas Society, Evans, and College of American Pathologists (CAP). GnP, gemcitabine plus nab-paclitaxel; BR, borderline resectable; UR, unresectable; N.D., not determined.
a, Two patients were received chemotherapy as a palliative therapy.